Author

Di Lu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

A small molecule ACT004 targets four-and-a-half LIM domain protein 1 to disrupt TGF-β/Smad signaling and promote FHL1 degradation in renal fibrosis.

Renal fibrosis is a common endpoint of chronic kidney disease (CKD), yet effective targeted anti-fibrotic therapies remain limited. Ovatodiolide (OVA) has anti-fibrotic activity but poor drug-like properties, whereas ACT004, a synthetic OVA derivative, has improved water solubility and metabolic stability. However, whe...

Xiao-Yang He, Fen-Fen Peng, Hui-Zhen Wang et al. · Pharmacological Research · 0 citations

Open access Aug 2026

Prognostic significance of positive margin-informed tumor status in esophageal squamous cell carcinoma using next-generation sequencing

Abstract Background Reliable prognostic biomarkers are urgently needed for operable esophageal squamous cell carcinoma (ESCC), as conventional histopathology often fails to detect minimal residual disease and accurately predict patient outcomes. Patients and Methods This study investigated the mutational patterns in ES...

Di Lu, Yu Tong, Chun-Hong He et al. · The Oncologist · 0 citations